Tags

Type your tag names separated by a space and hit enter

Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial.
Pain Med. 2008 Nov; 9(8):1202-8.PM

Abstract

OBJECTIVE

Neuropathic pain associated with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) can be intractable and may not respond to commonly used treatments, such as tricyclic antidepressants (TCAs) and opioids. This long-term, open-label study was a preliminary evaluation of pregabalin for patients whose pain had been judged refractory to other treatments for neuropathic pain.

DESIGN

Patients had previously participated in double-blind, placebo-controlled, randomized trials of pregabalin in DPN and PHN. They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e.g., other anticonvulsants, opioid, selective serotonin reuptake inhibitor, tramadol). Flexible-dosage pregabalin 150-600 mg/day was taken for 3-month periods followed by 3- to 28-day pregabalin "drug holidays," with an analysis up to 15 months (five treatment cycles). Pain intensity was measured using the visual analog scale of the Short-Form McGill Pain Questionnaire.

RESULTS

In total, 81 patients were included in this analysis. Pregabalin 150-600 mg/day was associated with clinically meaningful and sustained pain reduction during each treatment cycle. During pregabalin "drug holidays," pain quickly returned to baseline levels; it was reduced again when pregabalin was reinstated.

CONCLUSIONS

These results suggest that pregabalin may be beneficial in patients with neuropathic pain who have had an unsatisfactory response to treatment with other medications.

Authors+Show Affiliations

Department of Comprehensive Pain Center, Anesthesiology and Peri-Operative Medicine, Oregon Health & Science University, Portland, Oregon 97239, USA. staceyb@ohsu.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18346060

Citation

Stacey, Brett R., et al. "Pregabalin in the Treatment of Refractory Neuropathic Pain: Results of a 15-month Open-label Trial." Pain Medicine (Malden, Mass.), vol. 9, no. 8, 2008, pp. 1202-8.
Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med. 2008;9(8):1202-8.
Stacey, B. R., Dworkin, R. H., Murphy, K., Sharma, U., Emir, B., & Griesing, T. (2008). Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Medicine (Malden, Mass.), 9(8), 1202-8. https://doi.org/10.1111/j.1526-4637.2008.00423.x
Stacey BR, et al. Pregabalin in the Treatment of Refractory Neuropathic Pain: Results of a 15-month Open-label Trial. Pain Med. 2008;9(8):1202-8. PubMed PMID: 18346060.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. AU - Stacey,Brett R, AU - Dworkin,Robert H, AU - Murphy,Kevin, AU - Sharma,Uma, AU - Emir,Birol, AU - Griesing,Teresa, Y1 - 2008/03/11/ PY - 2008/3/19/pubmed PY - 2009/2/13/medline PY - 2008/3/19/entrez SP - 1202 EP - 8 JF - Pain medicine (Malden, Mass.) JO - Pain Med VL - 9 IS - 8 N2 - OBJECTIVE: Neuropathic pain associated with postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) can be intractable and may not respond to commonly used treatments, such as tricyclic antidepressants (TCAs) and opioids. This long-term, open-label study was a preliminary evaluation of pregabalin for patients whose pain had been judged refractory to other treatments for neuropathic pain. DESIGN: Patients had previously participated in double-blind, placebo-controlled, randomized trials of pregabalin in DPN and PHN. They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e.g., other anticonvulsants, opioid, selective serotonin reuptake inhibitor, tramadol). Flexible-dosage pregabalin 150-600 mg/day was taken for 3-month periods followed by 3- to 28-day pregabalin "drug holidays," with an analysis up to 15 months (five treatment cycles). Pain intensity was measured using the visual analog scale of the Short-Form McGill Pain Questionnaire. RESULTS: In total, 81 patients were included in this analysis. Pregabalin 150-600 mg/day was associated with clinically meaningful and sustained pain reduction during each treatment cycle. During pregabalin "drug holidays," pain quickly returned to baseline levels; it was reduced again when pregabalin was reinstated. CONCLUSIONS: These results suggest that pregabalin may be beneficial in patients with neuropathic pain who have had an unsatisfactory response to treatment with other medications. SN - 1526-4637 UR - https://www.unboundmedicine.com/medline/citation/18346060/Pregabalin_in_the_treatment_of_refractory_neuropathic_pain:_results_of_a_15_month_open_label_trial_ L2 - https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/j.1526-4637.2008.00423.x DB - PRIME DP - Unbound Medicine ER -